Drug Cost Optimization Using Evidence-Based Decision Support Systems

The article presents an overview of specialized medical information systems that perform ABC/VEN analysis. It provides a comparison of specific examples, describes their advantages and disadvantages, as well as the possibility of automating the processes of searching for information on the proven effectiveness of drugs, selecting alternative drugs within one ATC group, selecting alternative drugs within the framework of the current clinical recommendations of the Ministry of Health of the Russian Federation, assessing drug-drug interactions, as well as the reference information from the instructions for use of the drugs.

1. Gosudarstvennaya programma RF «Razvitie zdravookhraneniya», [Elektronnyj resurs]. URL: http://government.ru/rugovclassifier/855/ events/]. (in Russian)

2. Ukaz Prezidenta RF ot 06.06.2019 g. №254 «O strategii razvitiya zdravookhraneniya v Rossijskoj Federatsii na period do 2025 goda», [Elektronnyj resurs]. (in Russian)

3. Lebedev G.S., Fartushnyy E.N., Shaderkin I.A., Klimenko G.S., Ryabkov I.V., Kozhin P.B. et al. Bilding of the medical decision support system on the basis of providing medicine based on evidence-based medicine. Rossijskij Zhurnal Telemeditsiny i Elektronnogo Zdravookhraneniya. 2019; 1–2: 8–16. doi: https://doi.org/ 10.29188/2542-2413-2019-5-1-8-16. (in Russian)

4. Kazakova E.V. Monitoring naznacheniya i optimizatsiya ispol'zovaniya lekarstvennykh sredstv pri realizatsii programm gosudarstvennykh garantij (na primere Dal'nevostochnogo federal'nogo okruga): diss. … d-ra. med. nauk. Kh.: 2020. (in Russian)

5. Avxentyeva M.V., Omelyanovsky V.V. Perspectives of health technology assessment in the Russian Federation. Doctor.Ru. Internal Medicine. Clinical Sleep Medicine2015; 3 (104) — 4 (105): 12–16. (in Russian)

6. ГОСТ Р 56044–2014. Оценка медицинских технологий. Общие положения. М.: Стандартинформ, 2014; 111. [GOST R 56044–2014. Otsenka meditsinskikh tekhnologij. Obshchie polozheniya. M.: Standartinform, 2014; 111. (in Russian)

7. https://www.cochrane.org/ru/CD007026/STROKE_cerebrolizin-pri-ostrom-ishemicheskom-insulte

8. Natsional'nyj standart RF GOST R 57525-2017 «Kliniko-ekonomicheskie issledovaniya. Obshchie trebovaniya». (in Russian)

9. Gabbasova L.A., Shapovalova Y.S. The role of the ATC/DDD methodology in optimizing the practice of using antibacterial drugs in a multidisciplinary medical and preventive institution.Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2022; 3: 4–9. (in Russian)

10. Malaev M.G. Analysis of the effectiveness of the use of financial resources in the procurement of pharmaceuticals for state needs. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2021; 4: 75–79. https://doi.org/10.37489/ 2588-0519-2021-4-75-79. (in Russian)

11. World Health Organization. (2003). Drug and therapeutics committees: a practical guide. authors: Kathleen Holloway (ed.), Terry Green.

12. Loban D.S., Kruglikova A.V. ABC/VEN-analysis of drug consumption for the period of conversion for the treatment of COVID-19 infection. Molodezhny Innovatsionny Vestnik. 2022; 11: 230–232.(in Russian)

13. Khalafyan A.A., Koshkarov A.A., Fabritskaya E.Yu. Decision support system based on ABC/VEN-analysis of preferential drugs consumption. Fundamental Research. 2016; 4–2: 323–327. (in Russian)

14. Yevstigneev S.V., Titarenko A.F., Abakumova T.R., Alexandrova E.G., Khaziakhmetova V.N., Ziganshina L.E. Towards the rational use of medicines. Int J Risk Saf Med. 2015; 27 Suppl 1: S59–S60. doi: 10.3233/JRS150690.

15. Zhilevich L.A., Migal' T.F., Adamenko E.I., Gavrilenko L.N., Kozhanova I.N., Romanova I.S. Primenenie farmakoekonomicheskikh i farmakoepidemiologicheskikh metodov pri razrabotke lekarstvennogo formulyara gosudarstvennoj organizatsii zdravookhraneniya. Instruktsiya po primenenijyu. 2010. (in Russian)

16. Shulmin A.V., Leskova N.Y., Akulenok A.V., Solkin A.A., Konorev M.R., Shevtsova V.V. Management decision-making algorithms based on expert venanalysis. Vestnik Farmatsii. 2021 № 4 (94): 25–31. https://doi.org/ 10.52540/2074-9457.2021.4.25. (in Russian)

17. Shah H.M., Chung K.C. Archie Cochrane and his vision for evidencebased medicine. Plast Reconstr Surg. 2009 Sep; 124 (3): 982–988. doi: 10.1097/PRS.0b013e3181b03928

18. Sackett D. L., Rosenberg W. M. C., Gray J. A. M., Haynes R. B., Richardson W. S. Evidence based medicine: what it is and what it isn't. BMJ. 1996; 312: 71 doi:10.1136/bmj.312.7023.71.

19. Andreeva N.S., Rebrova O.Y., Zorin N.A., Avxentyeva M.V., Omelyanovsky V.V. Systems for assessing the reliability of scientific evidence and the soundness of Guidelines: comparison and prospects for unification. Meditsinskie Tekhnologii Otsenka i Vybor. 2012; 4. (in Russian)

20. GRADE Working Group. Grading quality of evidence and strength of recommendations Bmj. 2004; 328 (7454): 1490.

21. Amerikanskoe agentstvo po politike zdravookhraneniya i nauchnym issledovaniyam. http://www.ahrq.gov/browse/evidmed.htm

22. Mezhkollegial'naya meditsinskaya set'. http://www.sign.ac.uk

23. Oksfordskij tsentr dokazatel'noj meditsiny. http://www.cebm.net/index.aspx?o=1025

24. Elhelw B. Evidence-based medicine corner-grading the quality of evidence and the strength of recommendations: the Grade approach. Middle East Fertility Society Journal. 2006; 11 (1): 70–72.

25. Zhuravleva N.I., Shubina L.S., Sukhorukikh O.A. The use of the level of evidence and grade of recommendations scales in developing clinical guidelines in the Russian Federation. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019; 12 (1): 34–41. doi: https://doi.org/ 10.17749/2070-4909.2019.12.1.34-41. (in Russian)

26. Serritella A.V., Strohbehn G.W., Goldstein D.A., Lichter A.S., Ratain M.J. Interventional pharmacoeconomics: a novel mechanism for unlocking value. Clin PharmacolTher. 2020; 108 (3): 487–93. https://doi.org/10.1002/ cpt.1853.

27. Erivantseva T.N., Blokhina Yu.V. Artificial intelligence in healthcare: possibilities of patent protection. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (2): 270–76. doi: https://doi.org/10.17749/2070- 4909/farmakoekonomika.2021.063. (in Russian)

28. Kochetova E.A. The role of information technology in the implementation of pharmacogenetic testing in real clinical practice. Pharmacogenetics and Pharmacogenomics. 2016; 1: 29–34. (in Russian)

29. Bell G.C., Crews K.R., Wilkinson M.R., Haidar C.E., Hicks J.K., Baker D.K. et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014; 21 (e1): e93–99. doi: 10.1136/amiajnl-2013-001993.

30. http://pharmsuite.ru/web2/

31. Tcvetov V.M. PharmSuitePro — the automated workplace of clinical pharmacologist. Pharmacokinetics and Pharmacodynamics. 2016; 1: 54–55. (in Russian)

32. http://soft-medica.ru/service/farmcompile

33. https://www.ecp.umkb.com/ecp-analytics